CellSearch(TM) Circulating Tumor Cell Kit Receives FDA Clearance for Monitoring Patients with Metastatic Colorectal Cancer

Business Wire via NewsEdge Corporation :
Business Editors/Health/Medical Writers
HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--November 26, 2007--Immunicon Corporation (NASDAQ-GM:IMMC) announcedtoday that FDA clearance has been received for the CellSearch ™ Circulating Tumor Cell Kit as an aid in the monitoring of patients with metastatic colorectal cancer. The CellSearch test was originally cleared in 2004 for in vitro diagnostic use in patients with metastatic breast cancer. Serial testing for circulating tumor cell (CTC) count should be used in conjunction with other clinical methods for monitoring colorectal or breast cancer. Evaluation of CTC count at any time during the course of disease allows assessment of patient prognosis and is predictive of progression free survival and overall survival. The CellSearch Circulating Tumor Cell Kit, developed by Immunicon, is exclusively marketed by Veridex, LLC, in the cancer field.

read the full article: http://www.devicelink.com/newsedge/